Filing Details

Accession Number:
0001209191-19-002065
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-04 17:03:59
Reporting Period:
2019-01-03
Accepted Time:
2019-01-04 17:03:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1419600 Flexion Therapeutics Inc FLXN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1597407 D. Michael Clayman C/o Flexion Therapeutics, Inc.
10 Mall Road, Suite 301
Burlington MA 01803
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-01-03 3,278 $12.36 66,810 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 314,066 Indirect By the Michael D.Clayman 2006 Revocable Trust
Common Stock 24,600 Indirect By the Michael D. Clayman Irrevocable Trust
Common Stock 388,683 Indirect By Versant Development Fund III, LLC
Footnotes
  1. Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018.
  2. Includes 922 shares of Common Stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan.
  3. Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.